All In Biotech

Investigational drug · Phase 3

TPN171H

Also called: Simmerafil

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Erectile Dysfunction.

Phase 3

Last checked: Nov 20, 2026Latest source record: Jul 25, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

0 still active

All registered trials

14

Any phase or sponsor naming "TPN171H"

First trial start

2024

Apr 12, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "TPN171H", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Erectile Dysfunction

Approved drugs for the same conditions: Erectile dysfunction

Largest trials

Live from ClinicalTrials.gov: studies naming "TPN171H" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 3 on PubMed

Also in development for Erectile Dysfunction

  • TestofenPhase 32 trials

    RDC Clinical Pty Ltd · Long Covid19, Erectile Dysfunction

  • DTT106Phase 31 trial

    EMS · Prostatic Hyperplasia, Benign, Erectile Dysfunction

  • HGP1201Phase 31 trial

    Hanmi Pharmaceutical Company Limited · Erectile Dysfunction

  • HIP2602Phase 31 trial

    Hanmi Pharmaceutical Company Limited · Erectile Dysfunction

  • HPP2602-1Phase 31 trial

    Hanmi Pharmaceutical Company Limited · Erectile Dysfunction

  • HPP2602-2Phase 31 trial

    Hanmi Pharmaceutical Company Limited · Erectile Dysfunction

  • LIB-01Phase 21 trial

    Dicot AB · Erectile Dysfunction

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.